Logo
AZN logo
AstraZeneca PLC
AZN
204.03 (-0.47%) 0.96
Health Care
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Crestor Andexxa Onglyza Symlin XIGDUO XR Atacand Atacand HCT Atacand Plus Farxiga/Forxiga Plendil Modip Splendil Munobal Flodil Tenormin Tenormine Prenormine Atenol Zestril Brilinta/Brilique Komboglyze Qtern Wainua Byetta Lokelma Seloken ZOK Toprol-XL Betaloc ZOK XIGDUO Accolate Accoleit Vanticon Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Pulmicort Turbuhaler Symbicort Turbuhaler Airsupra Bricanyl Turbuhaler Fasenra Rhinocort Tezspire Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Saphnelo Breztri Aerosphere Duaklir Genuair Pulmicort Respules and Symbicort pMDI. It also provides Beyfortus Kavigale Evusheld Fluenz/FluMist Synagis Kanuma Ultomiris Koselugo Voydeya Soliris Strensiq Nexium and other medicines. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the Americas rest of Europe Asia Africa and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Quality Checklist 5/8

ROIC > 10%
Debt/Equity < 1
Net Margin > 10%
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
5Y Shares Out Change < 0%
Current Ratio > 1
Quick Ratio > 1
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $316.45(B)
EV: $358.14(B)
Total Equity: $48.72(B)
Earnings date: Apr-29-2026
P/E: 30.91
Forward P/E: 19.81
P/FCF: 26.88
P/S: 5.38
P/B: 6.50
EPS: $6.6
EPS (fwd): $10.3
FCF/share: $7.6
Revenue/share: $37.9
Book value/share: $31.4
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Debt/Equity: 0.61
Current Ratio: 0.90
Gross margin: 81.7%
Operating margin: 22.0%
Net margin: 17.4%
Dividend/share: $3.2
Div. yield: 1.57%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$58.74(B)
Gross profit$47.99(B)
EBITDA$19.28(B)
Net income$10.22(B)
Gross margin81.7%
Operating margin22.0%
Net margin17.4%
Shares outstanding1.55(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$114.07(B)
Current assets$28.72(B)
Total liabilities$65.36(B)
Current liabilities$30.62(B)
Cash & Short-term inv.$5.72(B)
Long-term debt$24.71(B)
Total intangibles$59.09(B)
PP&E$14.70(B)

Cash flow (TTM)

CFOCFICFF
FCF$11.77(B)
CapEx$-2.81(B)
Dividends paid$-4.85(B)
Stock issued$40.00(M)
Stock repurchased$-521.00(M)
Stock-based comp.$719.00(M)
Debt issued$379.00(M)
Debt repaid$-2.40(B)

Per share data (TTM)

Price: $204
Revenue: $37.9 (5.4x | 18.6%) Gross profit: $30.9 (6.6x | 15.2%) Earnings: $6.60 (30.9x | 3.2%)
FCF: $7.59 (26.9x | 3.7%) Stock-based Comp.: $0.46 (440.1x | 0.2%) CapEx.: $1.81 (112.6x | 0.9%) Dividend: $3.20 (63.8x | 1.6%)
Total Assets: $73.5 (2.8x | 36.0%) Total Liabilities: $42.1 (4.8x | 20.7%) Book Value: $31.4 (6.5x | 15.4%) Cash & ST inv.: $3.69 (55.3x | 1.8%) Debt: $15.9 (12.8x | 7.8%)
Earnings FY+1: $10.3 (19.8x | 5.0%) Earnings FY+2: $11.7 (17.5x | 5.7%) Earnings FY+3: $13.0 (15.7x | 6.4%) Earnings FY+4: $14.5 (14.1x | 7.1%) Earnings FY+5: $15.9 (12.8x | 7.8%)
FCF FY+1: $6.70 (30.4x | 3.3%) FCF FY+2: $8.68 (23.5x | 4.3%) FCF FY+3: $10.3 (19.9x | 5.0%) FCF FY+4: $10.4 (19.6x | 5.1%) FCF FY+5: $11.3 (18.1x | 5.5%)

Summary

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact